FindTrial
Sign In

Studying Blood Proteins and Genetic Signals in Liver Cancer

Biochemical Profiling of Sirtuins and associated Circulating MicroRNA Expression in LIRADS 4/5 Primary Hepatocellular Carcinoma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/07/114019
Enrollment
80
Registered
2026-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C220- Liver cell carcinoma

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Homi Bhabha Cancer Hospital & Mahamana Pandit Madan Mohan Malaviya Cancer Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients willing to give consent. Patients between age 18-75 years Newly diagnosed cases after multidisciplinary tumour board discussion LIRADS 4 & 5 on Triphasic CECT Eligibility criteria for healthy controls: Apparently Healthy Individuals between 18-75 years, with no history of malignant disorders or chronic illness and who are willing to give consent with Normal liver function test.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Participants not willing to give consent. Patients with malignancies other than Primary HCC, secondaries and metastasis, Critically ill patients with Performance status, Pregnant and lactating women, Patients with poor comprehension, neurodegenerative or psychiatric illness.

Design outcomes

Primary

MeasureTime frame
Primary Outcome: Plasma levels of Sirtuins SIRT1, SIRT3 in patients with LIRADS 4 & 5 Primary Hepatocellular Carcinoma and healthy controls. Correlation coefficient between plasma levels of Sirtuins in patients with LIRADS 4 & 5 Primary Hepatocellular Carcinoma and healthy controls Timepoint: Study Duration - 18months Study Commencement- 08/08/2026 Date of Completion- 08/08/2028—

Secondary

MeasureTime frame
Secondary Outcome: Comparison of expression levels of circulating microRNAs in patients with LIRADS 4 & 5 Primary Hepatocellular Carcinoma and healthy controls Timepoint: Study Duration - 18months Study Commencement- 08/08/2026 Date of Completion- 08/08/2028;Exploratory Outcome: Correlation Coefficient of plasma MicroRNA with Sirtuin targets and AFP, PIVKA II and GAAD score with Barcelona Clinic Liver Cancer Staging. Baseline variation of selected sirtuin targeting microRNAs among cases and healthy controlsTimepoint: Study Duration - 18months Study Commencement- 08/08/2026 Date of Completion- 08/08/2028—

Countries

India

Contacts

Public ContactPratibha Gavel

HOMI BHABHA CANCER HOSPITAL & MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE, VARANASI

pratibhagavel@gmail.com9670061741

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026